Empagliflozin 25 MG ( DrugBank: Empagliflozin )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
72	下垂体性ADH分泌異常症	1

72. 下垂体性ADH分泌異常症

---

臨床試験数 : 41 /  薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447911 (ClinicalTrials.gov)	February 4, 2021	10/6/2020	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia	Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)	Hyponatremia;SIADH;Liver Failure;Kidney Failure	Drug: Empagliflozin 25 MG;Drug: Placebo	University Hospital, Basel, Switzerland	Luzerner Kantonsspital;Centre Hospitalier Universitaire Vaudois	Recruiting	18 Years	N/A	All	172	Phase 4	Switzerland